Digital Diabetes Global Market-Forecast to 2026

Publishing Date : January, 2020
Report Code : HCMD0164
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Digital diabetes includes products utilizing advanced technologies for monitoring, managing and tools that help in deciding optimum therapy options in the patients suffering from diabetes. These devices help in monitoring of blood sugar levels, calorie counting, and in insulin dose calculation, reduce complications to improve the quality of life of diabetics. According to IQ4I analysis, digital diabetes global market expected to reach $16,329.6 million by 2026 growing at a high single digit CAGR from 2019 to 2026.

The digital diabetes global market is segmented based on products, end-users and geography. The product market is further segmented into devices and apps and software. As estimated by IQ4I Research, the devices global market is expected to grow at a mid single CAGR from 2019 to 2026. The apps and software global market is expected to grow at a strong double digit CAGR from 2019 to 2026 due to growing adoption of digital solutions such as cloud based software, technology advancements such as incorporating artificial intelligence to manage the diabetes are driving the market. However, privacy and data safety issues, stringent regulatory approvals, lack of reimbursement are restraining the market growth.

The digital diabetes devices global market by product type is segmented into SBGM, CGM, Smart Insulin Pumps, and Smart Insulin Pens. CGM accounted for the largest market revenue in 2019 and is expected to grow at a double digit CAGR from 2019 to 2026 due to increasing number of regulatory approvals for CGM systems; technological advancements in devices and other pipeline devices. SBGM products are further segmented into Smart Blood glucose meter, Blood glucose testing-strips, Lancets and control solution. Blood glucose testing-strips accounted largest revenue in 2019. CGM products are further segmented into glucose sensors and transmitter and receiver. Glucose sensor commanded the largest revenue in 2019 and is expected to grow at a double digit CAGR due to increasing adoption of CGM systems, development of advanced CGM systems, and favourable government policies in developed countries promoting the adoption of CGM systems. The smart insulin pump products are further segmented into traditional insulin pump and patch pump. Traditional insulin pump held the largest revenue in 2019 and expected to grow at a mid single digit CAGR from 2019 to 2026 and Patch pump is expected to grow at a double digit CAGR from 2019 to 2026.

The Digital diabetes end-user market is segmented into home care, hospitals & private clinics and others which include ambulatory setting, academic and research institutes. Homecare accounted for largest revenue in 2019. The largest revenue of this segment can be mainly attributed to technological advancements and a shift toward home care and self-management of diabetes, an increase in prevalence of diabetes disease, the improvement and acceptance of home care devices has increased. In addition, the growing focus of companies to increase awareness about diabetes and glucose management devices & apps are further driving the adoption in home care settings. Homecare is the fastest growing segment with projected high single digit CAGR from 2019 to 2026 due to the increase of self management of diabetes using apps and software at home itself.

Geographical wise, the North America region commanded the largest revenue in 2019 and expected to grow at a mid single digit CAGR from 2019 to 2026. Some of the driving factors are increased awareness of the benefits of using continuous glucose monitoring systems, growing diffusion of smart devices, increasing prevalence and incidences of diabetes due to obesity and better accessibility to technologies compared to other regions and presence of well-established distribution channels of the major players in this region. However, Asia-Pacific region is expected to grow at a double digit strong CAGR from 2019 to 2026 due to a large pool of patients with diabetes, increasing patient awareness about diabetes, and increasing affordability of advanced treatment due to increasing prosperity.

The digital diabetes global market is a competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares and also acquiring companies for product expansion. Some of the key players in the digital diabetes global market are Abbott Laboratories (U.S.), Dexcom, Inc. (U.S.), Insulet Corporation (U.S.), i-Sens, Inc (South Korea), Livongo Health, Inc. (U.S.), Medtronic PLC (Ireland), F.Hoffmann-LA Roche AG (Switzerland), Senseonics Holdings Inc. (U.S.), Tandem Diabetes Care (U.S.), and Ypsomed Holding AG (Switzerland).

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America (U.S. and Rest of N.A.)
  • Europe (Germany, France, Italy and Rest of E.U.)
  • Asia-Pacific  (Japan, China, India and Rest of APAC)
  • Rest of the World (RoW) (Brazil, Rest of Latin-America and Middle East & Others)
  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     SCOPE OF THE REPORT
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     THE GLOBAL RISE IN THE PREVALENCE AND INCIDENCE OF DIABETES
        • 3.3.1.2     TECHNOLOGICAL ADVANCEMENTS IN DIGITAL DIABETES DEVICES
        • 3.3.1.3     GROWING DIFFUSION OF SMART DEVICES AND DIGITAL PLATFORMS
        • 3.3.1.4     INCREASING R & D INVESTMENTS
      • 3.3.2     RESTRAINS AND THREATS
        • 3.3.2.1     HIGH COST ASSOCIATED WITH THE PRODUCTS
        • 3.3.2.2     PRODUCT RECALLS
        • 3.3.2.3     INADEQUATE REIMBURSEMENT
        • 3.3.2.4     STRICT REGULATION OF GLUCOSE MONITORING DEVICES BY REGULATORY ORGANIZATIONS LIKE THE FDA AND OTHERS
        • 3.3.2.5     PRIVACY CONCERN AND SAFETY ISSUES IN DIGITAL DIABETES
    • 3.4     MARKET SHARE ANALYSIS
      • 3.4.1     DIGITAL DIABETES GLOBAL MARKET SHARE ANALYSIS
      • 3.4.2     CONTINUOUS GLUCOSE MONITOR (CGM) MARKET SHARE ANALYSIS
      • 3.4.3     SMART INSULIN PUMP MARKET SHARE ANALYSIS
    • 3.5     REGULATORY AFFAIRS
      • 3.5.1     U.S.
      • 3.5.2     EUROPE
      • 3.5.3     CHINA
      • 3.5.4     INDIA
      • 3.5.5     JAPAN
    • 3.6     TECHNOLOGICAL ADVANCEMENTS
      • 3.6.1     ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING
    • 3.7     CLINICAL TRIALS
    • 3.8     FUNDING SCENARIO
    • 3.9     DIGITAL DIABETES – DEALS, APPROVALS AND NEW PRODUCT LAUNCH
    • 3.10     APPROVAL
    • 3.11     FDA AND CE APPROVED DIABETES MANAGEMENT APPS
    • 3.12     PRODUCT LAUNCH
    • 3.13     REVENUE MODEL
      • 3.13.1     INTRODUCTION
      • 3.13.2     FREEMIUM MODEL
      • 3.13.3     THIRD PARTY PAYMENT MODEL
      • 3.13.4     DIFFERENT REVENUE STREAMS MODEL
      • 3.13.5     LOWER PRICING MODEL
      • 3.13.6     NEW PAYMENT MODEL OR NEW PRICING MODEL
    • 3.14     PORTER’S FIVE FORCE ANALYSIS
      • 3.14.1     THREAT OF NEW ENTRANTS
      • 3.14.2     THREAT OF SUBSTITUTES
      • 3.14.3     BARGAINING POWER OF SUPPLIERS
      • 3.14.4     BARGAINING POWER OF BUYERS
      • 3.14.5     RIVALRY AMONG EXISTING COMPETITORS
    • 3.15     PATENT ANALYSIS
    • 3.16     UNITS SOLD
      • 3.16.1     GLUCOSE TESTING STRIPS UNITS SOLD
      • 3.16.2     CGM SENSORS UNITS SOLD
      • 3.16.3     SMART INSULIN PUMP UNITS SOLD
      • 3.16.4     SMART INSULIN PEN UNITS SOLD
    • 3.17     MARKET PENETRATION
  • 4     DIGITAL DIABETES GLOBAL MARKET, BY PRODUCTS
    • 4.1     INTRODUCTION
    • 4.2     DEVICES
      • 4.2.1     SMART BLOOD GLUCOSE MONITORING(SBGM)
        • 4.2.1.1     SMART BLOOD GLUCOSE METER
        • 4.2.1.2     BLOOD GLUCOSE TESTING STRIPS
        • 4.2.1.3     LANCETS
        • 4.2.1.4     OTHERS
      • 4.2.2     CONTINUOUS GLUCOSE MONITORING (CGM)
        • 4.2.2.1     GLUCOSE SENSORS
        • 4.2.2.2     TRANSMITTER AND RECEIVERS
      • 4.2.3     SMART INSULIN PUMP
        • 4.2.3.1     TRADITIONAL INSULIN PUMP
        • 4.2.3.2     PATCH INSULIN PUMP
      • 4.2.4     SMART INSULIN PEN
    • 4.3     APPS AND SOFTWARE
  • 5     DIGITAL DIABETES GLOBAL MARKET, BY END-USERS
    • 5.1     INTRODUCTION
    • 5.2     HOME CARE
    • 5.3     HOSPITALS AND PRIVATE CLINICS
    • 5.4     OTHERS
  • 6     REGIONAL ANALYSIS
    • 6.1     INTRODUCTION
    • 6.2     NORTH AMERICA
      • 6.2.1     U.S.
      • 6.2.2     REST OF N.A.
    • 6.3     EUROPE
      • 6.3.1     GERMANY
      • 6.3.2     FRANCE
      • 6.3.3     ITALY
      • 6.3.4     REST OF EUROPE
    • 6.4     ASIA - PACIFIC
      • 6.4.1     JAPAN
      • 6.4.2     CHINA
      • 6.4.3     INDIA
      • 6.4.4     REST OF APAC
    • 6.5     REST OF THE WORLD
      • 6.5.1     BRAZIL
      • 6.5.2     REST OF LATIN AMERICA
      • 6.5.3     MIDDLE EAST & OTHERS
  • 7     COMPETITIVE LANDSCAPE
    • 7.1     INTRODUCTION
    • 7.2     COLLABORATION, AGREEMENTS AND PARTNERSHIPS
    • 7.3     APPROVALS
    • 7.4     NEW PRODUCT LAUNCH
    • 7.5     ACQUISITION
    • 7.6     EXPANSION
    • 7.7     OTHER DEVELOPMENTS
  • 8     MAJOR PLAYER PROFILES
    • 8.1     ABBOTT LABORATORIES
      • 8.1.1     OVERVIEW
      • 8.1.2     FINANCIALS
      • 8.1.3     PRODUCT PORTFOLIO
      • 8.1.4     KEY DEVELOPMENTS
      • 8.1.5     BUSINESS STRATEGY
      • 8.1.6     SWOT ANALYSIS
    • 8.2     DEXCOM, INC
      • 8.2.1     OVERVIEW
      • 8.2.2     FINANCIALS
      • 8.2.3     PRODUCT PORTFOLIO
      • 8.2.4     KEY DEVELOPMENTS
      • 8.2.5     BUSINESS STRATEGY
      • 8.2.6     SWOT ANALYSIS
    • 8.3     F. HOFFMANN-LA ROCHE AG.
      • 8.3.1     OVERVIEW
      • 8.3.2     FINANCIALS
      • 8.3.3     PRODUCT PORTFOLIO
      • 8.3.4     KEY DEVELOPMENTS
      • 8.3.5     BUSINESS STRATEGY
      • 8.3.6     SWOT ANALYSIS
    • 8.4     INSULET CORPORATION
      • 8.4.1     OVERVIEW
      • 8.4.2     FINANCIALS
      • 8.4.3     PRODUCT PORTFOLIO
      • 8.4.4     KEY DEVELOPMENTS
      • 8.4.5     BUSINESS STRATEGY
      • 8.4.6     SWOT ANALYSIS
    • 8.5     I-SENS, INC.
      • 8.5.1     OVERVIEW
      • 8.5.2     FINANCIALS
      • 8.5.3     KEY DEVELOPMENTS
      • 8.5.4     PRODUCT PORTFOLIO
      • 8.5.5     BUSINESS STRATEGY
      • 8.5.6     SWOT ANALYSIS
    • 8.6     LIVONGO HEALTH, INC.
      • 8.6.1     OVERVIEW
      • 8.6.2     FINANCIALS
      • 8.6.3     KEY DEVELOPMENTS
      • 8.6.4     PRODUCT PORTFOLIO
      • 8.6.5     BUSINESS STRATEGY
      • 8.6.6     SWOT ANALYSIS
    • 8.7     MEDTRONIC, PLC
      • 8.7.1     OVERVIEW
      • 8.7.2     FINANCIALS
      • 8.7.3     PRODUCT PORTFOLIO
      • 8.7.4     KEY DEVELOPMENTS
      • 8.7.5     BUSINESS STRATEGY
      • 8.7.6     SWOT ANALYSIS
    • 8.8     SENSEONICS HOLDINGS, INC.
      • 8.8.1     OVERVIEW
      • 8.8.2     FINANCIALS
      • 8.8.3     PRODUCT PORTFOLIO
      • 8.8.4     KEY DEVELOPMENTS
      • 8.8.5     BUSINESS STRATEGY
      • 8.8.6     SWOT ANALYSIS
    • 8.9     TANDEM DIABETES CARE INC.
      • 8.9.1     OVERVIEW
      • 8.9.2     FINANCIALS
      • 8.9.3     PRODUCT PORTFOLIO
      • 8.9.4     KEY DEVELOPMENTS
      • 8.9.5     BUSINESS STRATEGY
      • 8.9.6     SWOT ANALYSIS
    • 8.10     YPSOMED HOLDING AG.
      • 8.10.1     OVERVIEW
      • 8.10.2     FINANCIALS
      • 8.10.3     PRODUCT PORTFOLIO
      • 8.10.4     KEY DEVELOPMENTS
      • 8.10.5     BUSINESS STRATEGY
      • 8.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     DIGITAL DIABETES GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 2     SELF-MONITORING GLUCOSE TESTING STRIPS GLOBAL UNITS SOLD, BY REGION, (2018-2026) (NO’S)
      • TABLE 3     CGM SENSORS GLOBAL UNITS SOLD, BY REGION, (2018-2026) (N0’S)
      • TABLE 4     SMART INSULIN PUMP GLOBAL UNITS SOLD, BY REGION, (2018-2026) (NO’S)
      • TABLE 5     SMART INSULIN PEN GLOBAL UNITS SOLD, BY REGION, (2018-2026) (NO’S)
      • TABLE 6     DIGITAL DIABETES GLOBAL MARKET REVENUE, BY PRODUCTS, (2018-2026) ($MN)
      • TABLE 7     DIGITAL DIABETES DEVICES GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 8     DIGITAL DIABETES DEVICES GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
      • TABLE 9     SBGM GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 10     SMART BLOOD GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY PRODUCTS, (2018-2026) ($MN)
      • TABLE 11     SMART BLOOD GLUCOSE METER GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 12     BLOOD GLUCOSE TESTING STRIPS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 13     LANCETS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 14     OTHERS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 15     CGM GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 16     CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY PRODUCTS, (2018-2026) ($MN)
      • TABLE 17     CGM GLUCOSE SENSORS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 18     TRANSMITTER AND RECEIVER GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 19     SMART INSULIN PUMP GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 20     SMART INSULIN PUMP GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
      • TABLE 21     TRADITIONAL INSULIN PUMP GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 22     PATCH INSULIN PUMP GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 23     SMART INSULIN PEN GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 24     APPS AND SOFTWARE GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 25     DIGITAL DIABETES GLOBAL MARKET REVENUE, BY END-USER, (2018-2026) ($MN)
      • TABLE 26     DIGITAL DIABETES HOMECARE GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 27     DIGITAL DIABETES HOSPITAL & PRIVATE CLINICS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 28     DIGITAL DIABETES OTHERS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 29     DIGITAL DIABETES GLOBAL MARKET REVENUE, BY REGION (2018 - 2026) ($MN)
      • TABLE 30     NORTH AMERICA DIGITAL DIABETES MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
      • TABLE 31     NORTH AMERICA DIGITAL DIABETES DEVICES MARKET REVENUE, BY PRODUCT TYPE (2018-2026) ($MN)
      • TABLE 32     NORTH-AMERICA SBGM MARKET REVENUE, BY PRODUCTS, (2018-2026) ($MN)
      • TABLE 33     NORTH AMERICA CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
      • TABLE 34     NORTH AMERICA SMART INSULIN PUMP MARKET REVENUE, BY PRODUCT TYPE (2018-2026) ($MN)
      • TABLE 35     NORTH AMERICA DIGITAL DIABETES MARKET REVENUE, BY END-USER (2018-2026) ($MN)
      • TABLE 36     NORTH AMERICA DIGITAL DIABETES MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
      • TABLE 37     EUROPE DIGITAL DIABETES MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
      • TABLE 38     EUROPE DIGITAL DIABETES DEVICES MARKET REVENUE, BY PRODUCT TYPE (2018-2026) ($MN)
      • TABLE 39     EUROPE SBGM MARKET REVENUE, BY PRODUTS, (2018-2026)($MN)
      • TABLE 40     EUROPE CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
      • TABLE 41     EUROPE SMART INSULIN PUMP MARKET REVENUE, BY PRODUCT TYPE (2018-2026) ($MN)
      • TABLE 42     EUROPE DIGITAL DIABETES MARKET REVENUE, BY END-USER (2018-2026) ($MN)
      • TABLE 43     EUROPE DIGITAL DIABETES MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
      • TABLE 44     APAC DIGITAL DIABETES MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
      • TABLE 45     APAC DIGITAL DIABETES DEVICES MARKET REVENUE, BY PRODUCT TYPE (2018-2026) ($MN)
      • TABLE 46     APAC SBGM MARKET REVENUE, BY PRODUCTS, (2018-2026) ($MN)
      • TABLE 47     APAC CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
      • TABLE 48     APAC SMART INSULIN PUMP MARKET REVENUE, BY PRODUCT TYPE (2018-2026) ($MN)
      • TABLE 49     APAC DIGITAL DIABETES MARKET REVENUE, BY END-USER (2018-2026) ($MN)
      • TABLE 50     APAC DIGITAL DIABETES MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
      • TABLE 51     ROW DIGITAL DIABETES MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
      • TABLE 52     ROW DIGITAL DIABETES DEVICES MARKET REVENUE, BY PRODUCT TYPE (2018-2026) ($MN)
      • TABLE 53     ROW SBGM MARKET REVENUE, BY PRODUCTS, (2018-2026) ($MN)
      • TABLE 54     ROW CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
      • TABLE 55     ROW SMART INSULIN PUMP MARKET REVENUE, BY PRODUCT TYPE (2018-2026) ($MN)
      • TABLE 56     ROW DIGITAL DIABETES MARKET REVENUE, BY END-USER (2018-2026) ($MN)
      • TABLE 57     ROW DIGITAL DIABETES MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
      • TABLE 58     APPROVALS
      • TABLE 59     NEW PRODUCT LAUNCH
      • TABLE 60     ACQUISITION
      • TABLE 61     EXPANSION
      • TABLE 62     OTHER DEVELOPMENTS
      • TABLE 63     ABBOTT LABORATORIES, INC: TOTAL REVENUE AND R&D EXPENSES, (2017-2019)(Q3) ($MN)
      • TABLE 64     ABBOTT LABORATORIES, INC: TOTAL REVENUE, BY SEGMENTS, (2017-2019) (Q3) ($MN)
      • TABLE 65     ABBOTT LABORATORIES, INC: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) (Q3) ($MN)
      • TABLE 66     DEXCOM, INC: TOTAL REVENUE AND R&D EXPENSES (2017-2019) (Q3) ($MN)
      • TABLE 67     DEXCOM INC: TOTAL REVENUE, BY SEGMENTS (2017-2019) (Q3) ($MN)
      • TABLE 68     DEXCOM INC: TOTAL REVENUE, BY GEOGRAPHY (2017-2019) (Q3) ($MN)
      • TABLE 69     F.HOFFMANN-LA ROCHE AG: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
      • TABLE 70     F.HOFFMANN-LA ROCHE AG: TOTAL REVENUE BY SEGMENTS, (2017-2019) (Q3) ($MN)
      • TABLE 71     F.HOFFMANN-LA ROCHE AG: DIAGNOSTICS REVENUE, BY SEGMENT, (2017-2019) (Q3) ($MN)
      • TABLE 72     F.HOFFMANN-LA ROCHE AG: DIABETES CARE REVENUE, BY GEOGRAPHY, (2017-2019) (Q3) ($MN)
      • TABLE 73     ROCHE HOLDINGS AG: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) (Q3) ($MN)
      • TABLE 74     INSULET CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
      • TABLE 75     INSULET CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2017-2019) (Q3) ($MN)
      • TABLE 76     INSULET CORPORATION: TOTAL REVENUE, BY GEOGRAPHY (2017-2019) (Q3) ($MN)
      • TABLE 77     LIVONGO HEALTH, INC. : TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
      • TABLE 78     MEDTRONIC, PLC: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q2) ($MN)
      • TABLE 79     MEDTRONIC, PLC: TOTAL REVENUE, BY SEGMENTS, (2017-2019) (Q2) ($MN)
      • TABLE 80     MEDTRONIC, PLC: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) (Q2) ($MN)
      • TABLE 81     SENSEONICS HOLDINGS, INC.: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
      • TABLE 82     SENSEONICS HOLDINGS, INC.: TOTAL REVENUE, BY GEOGRAPHY (2017-2019) (Q3) ($MN)
      • TABLE 83     TANDEM DIABETES CARE, INC.: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
      • TABLE 84     TANDEM DIABETES CARE, INC.: TOTAL REVENUE, BY SEGMENTS, (2017-2019) (Q3) ($MN)
      • TABLE 85     TANDEM DIABETES CARE, INC.: TOTAL REVENUE, BY GEOGRAPHY (2017-2019) (Q3) ($MN)
      • TABLE 86     YPSOMED HOLDING AG: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q2) ($MN)
      • TABLE 87     YPSOMED HOLDING AG: TOTAL REVENUE, BY SEGMENTS, (2017-2019) (Q2) ($MN)
      • TABLE 88     YPSOMED HOLDING AG: TOTAL REVENUE, BY GEOGRAPHY (2017-2019)(Q2) ($MN)

      LIST OF FIGURES

      • FIGURE 1     DIGITAL DIABETES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: DIGITAL DIABETES GLOBAL MARKET
      • FIGURE 3     DIGITAL DIABETES GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     DIGITAL DIABETES GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     DIGITAL DIABETES GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
      • FIGURE 6     DIGITAL DIABETES GLOBAL MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     DIGITAL DIABETES GLOBAL MARKET SHARE, BY MAJOR PLAYERS (2019) (%)
      • FIGURE 9     DIGITAL DIABETES GLOBAL CGM MARKET SHARE, BY MAJOR PLAYERS (2019) (%)
      • FIGURE 10     SMART INSULIN PUMP GLOBAL MARKET SHARE, BY MAJOR PLAYERS (2019) (%)
      • FIGURE 11     DIGITAL DIABETES MARKET: PORTER’S ANALYSIS
      • FIGURE 12     DIGITAL DIABETES GLOBAL MARKET: PATENT FILING, BY MAJOR PLAYERS (2015-2019)
      • FIGURE 13     SELF MONITORING GLUCOSE TEST STRIPS GLOBAL UNITS SOLD, BY REGION AND COUNTRYWISE (2019) (NO’S)
      • FIGURE 14     CGM SENSORS GLOBAL UNITS SOLD, BY REGION AND COUNTRYWISE (2019) (NO’S)
      • FIGURE 15     SMART INSULIN PUMP GLOBAL UNITS SOLD, BY REGION AND COUNTRYWISE (2019) (NO’S)
      • FIGURE 16     SMART INSULIN PEN GLOBAL UNITS SOLD, BY REGION AND COUNTRYWISE (2019) (NO’S)
      • FIGURE 17     SMART INSULIN PENS MARKET PENETRATION, (2019)
      • FIGURE 18     SMART INSULIN PUMP MARKET PENETRATION, (2019)
      • FIGURE 19     DIGITAL DIABETES GLOBAL MARKET SHARE, BY PRODUCTS (2019 VS 2026) (%)
      • FIGURE 20     DIGITAL DIABETES DEVICES GLOBAL MARKET SHARE, BY REGION (2019 VS 2026) (%)
      • FIGURE 21     DIGITAL DIABETES DEVICES GLOBAL MARKET SHARE, BY PRODUCT TYPE (2019 VS 2026) (%)
      • FIGURE 22     SBGM GLOBAL MARKET SHARE, BY REGION (2019 VS 2026) (%)
      • FIGURE 23     SMART BLOOD GLUCOSE MONITORING GLOBAL MARKET SHARE, BY PRODUCTS (2019 VS 2026) (%)
      • FIGURE 24     SMART BLOOD GLUCOSE METER MARKET SHARE, BY REGION (2019 VS 2026) (%)
      • FIGURE 25     BLOOD GLUCOSE TESTING STRIPS MARKET SHARE, BY REGION (2019 VS 2026) (%)
      • FIGURE 26     LANCETS GLOBAL MARKET SHARE, BY REGION (2019 VS 2026) (%)
      • FIGURE 27     OTHERS GLOBAL MARKET SHARE, BY REGION (2019 VS 2026) (%)
      • FIGURE 28     CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY PRODUCTS (2019 VS 2026) ($MN)
      • FIGURE 29     SMART INSULIN PUMP GLOBAL MARKET SHARE, BY REGION (2019 VS 2026) (%)
      • FIGURE 30     SMART INSULIN PUMP GLOBAL MARKET REVENUE, BY PRODUCT TYPE (2019 VS 2026) ($MN)
      • FIGURE 31     PATCH INSULIN PUMP GLOBAL MARKET SHARE, BY REGION (2019 VS 2026) (%)
      • FIGURE 32     SMART INSULIN PEN GLOBAL MARKET SHARE, BY REGION (2019 VS 2026) (%)
      • FIGURE 33     APPS AND SOFTWARE GLOBAL MARKET SHARE, BY REGION (2019 VS 2026) (%)
      • FIGURE 34     DIGITAL DIABETES GLOBAL MARKET SHARE, BY END-USER (2019 VS 2026) (%)
      • FIGURE 35     DIGITAL DIABETES HOMECARE GLOBAL MARKET SHARE, BY REGION (2019 VS 2026) (%)
      • FIGURE 36     DIGITAL DIABETES HOSPITAL AND PRIVATE CLINICS GLOBAL MARKET SHARE, BY REGION (2019 VS 2026) (%)
      • FIGURE 37     DIGITAL DIABETES OTHERS GLOBAL MARKET SHARE, BY REGION (2019 VS 2026) (%)
      • FIGURE 38     DIGITAL DIABETES GLOBAL MARKET REVENUE, BY REGION (2018 - 2026) ($MN)
      • FIGURE 39     NORTH AMERICA DIGITAL DIABETES MARKET SHARE, BY PRODUCTS (2019 VS 2026) (%)
      • FIGURE 40     NORTH AMERICA DIGITAL DIABETES DEVICES MARKET SHARE, BY PRODUCT TYPE (2019 VS 2026) (%)
      • FIGURE 41     NORTH AMERICA SBGM MARKET SHARE, BY PRODUCTS (2019 VS 2026) (%)
      • FIGURE 42     NORTH AMERICA CGM MARKET REVENUE, BY PRODUCTS (2019 VS 2026) ($MN)
      • FIGURE 43     NORTH AMERICA SMART INSULIN PUMP MARKET REVENUE, BY PRODUCT TYPE (2019 VS 2026) ($MN)
      • FIGURE 44     NORTH AMERICA DIGITAL DIABETES MARKET SHARE, BY END-USER (2019 VS 2026) (%)
      • FIGURE 45     NORTH AMERICA DIGITAL DIABETES MARKET SHARE, BY COUNTRY (2019 VS 2026) (%)
      • FIGURE 46     N.A. SMART INSULIN PUMP AND SMART INSULIN PEN MARKET PENETRATION, (2019)
      • FIGURE 47     U.S. DIGITAL DIABETES MARKET REVENUE, BY PRODUCTS (2019 VS 2026) ($MN)
      • FIGURE 48     U.S. DIGITAL DIABETES DEVICES MARKET REVENUE, BY PRODUCT TYPE (2019 VS 2026) ($MN)
      • FIGURE 49     U.S. DIGITAL DIABETES MARKET REVENUE, BY END-USER (2019 VS 2026) ($MN)
      • FIGURE 50     REST OF N.A. DIGITAL DIABETES MARKET REVENUE, BY PRODUCTS (2019 VS 2026) ($MN)
      • FIGURE 51     REST OF N.A. DIGITAL DIABETES DEVICES MARKET REVENUE, BY PRODUCT TYPE (2019 VS 2026) ($MN)
      • FIGURE 52     REST OF N.A. DIGITAL DIABETES MARKET REVENUE, BY END-USER (2019 VS 2026) ($MN)
      • FIGURE 53     EUROPE DIGITAL DIABETES MARKET SHARE, BY PRODUCTS (2019 VS 2026) (%)
      • FIGURE 54     EUROPE DIGITAL DIABETES DEVICES MARKET SHARE, BY PRODUCT TYPE (2019 VS 2026) (%)
      • FIGURE 55     EUROPE SBGM MARKET SHARE, BY PRODUCTS (2019 VS 2026) (%)
      • FIGURE 56     EUROPE CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019 VS 2026) ($MN)
      • FIGURE 57     EUROPE SMART INSULIN PUMP MARKET REVENUE, BY PRODUCT TYPE (2019 VS 2026) ($MN)
      • FIGURE 58     EUROPE DIGITAL DIABETES MARKET SHARE, BY END-USER (2019 VS 2026) (%)
      • FIGURE 59     EUROPE DIGITAL DIABETES MARKET SHARE, BY COUNTRY (2019 VS 2026) (%)
      • FIGURE 60     EUROPE SMART INSULIN PUMPS AND SMART INSULIN PEN MARKET PENETRATION, (2019)
      • FIGURE 61     GERMANY DIGITAL DIABETES MARKET REVENUE, BY PRODUCT, (2019 VS 2026) ($MN)
      • FIGURE 62     GERMANY DIGITAL DIABETES DEVICES MARKET REVENUE, BY PRODUCT TYPE (2019 VS 2026) ($MN)
      • FIGURE 63     GERMANY DIGITAL DIABETES MARKET REVENUE, BY END-USER (2019 VS 2026) ($MN)
      • FIGURE 64     FRANCE DIGITAL DIABETES MARKET REVENUE, BY PRODUCTS (2019 VS 2026) ($MN)
      • FIGURE 65     FRANCE DIGITAL DIABETES DEVICES MARKET REVENUE, BY PRODUCT TYPE (2019 VS 2026) ($MN)
      • FIGURE 66     FRANCE DIGITAL DIABETES MARKET REVENUE, BY END-USER (2019 VS 2026) ($MN)
      • FIGURE 67     ITALY DIGITAL DIABETES MARKET REVENUE, BY PRODUCTS (2019 VS 2026) ($MN)
      • FIGURE 68     ITALY DIGITAL DIABETES DEVICES MARKET REVENUE, BY PRODUCT TYPE (2019 VS 2026) ($MN)
      • FIGURE 69     ITALY DIGITAL DIABETES MARKET REVENUE, BY END-USER (2019 VS 2026) ($MN)
      • FIGURE 70     REST OF E.U. DIGITAL DIABETES MARKET REVENUE, BY PRODUCTS (2019 VS 2026) ($MN)
      • FIGURE 71     REST OF E.U. DIGITAL DIABETES DEVICES MARKET REVENUE, BY PRODUCT-TYPE (2019 VS 2026) ($MN)
      • FIGURE 72     REST OF E.U DIGITAL DIABETES MARKET REVENUE, BY END-USER (2019 VS 2026) ($MN)
      • FIGURE 73     APAC DIGITAL DIABETES MARKET SHARE, BY PRODUCTS (2019 VS 2026) (%)
      • FIGURE 74     APAC DIGITAL DIABETES DEVICES MARKET SHARE, BY PRODUCT TYPE (2019 VS 2026) (%)
      • FIGURE 75     APAC SBGM MARKET SHARE, BY PRODUCTS (2019 VS 2026) (%)
      • FIGURE 76     APAC CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019 VS 2026) ($MN)
      • FIGURE 77     APAC SMART INSULIN PUMP MARKET REVENUE, BY PRODUCT TYPE (2019 VS 2026) ($MN)
      • FIGURE 78     APAC DIGITAL DIABETES MARKET SHARE, BY END-USER (2019 VS 2026) (%)
      • FIGURE 79     APAC DIGITAL DIABETES MARKET SHARE, BY COUNTRY (2019 VS 2026) (%)
      • FIGURE 80     APAC SMART INSULIN PUMPS AND SMART INSULIN PENS MARKET PENETRATION, (2019)
      • FIGURE 81     JAPAN DIGITAL DIABETES MARKET REVENUE, BY PRODUCTS, (2019 VS 2026) ($MN)
      • FIGURE 82     JAPAN DIGITAL DIABETES DEVICES MARKET REVENUE, BY PRODUCT TYPE (2019 VS 2026) ($MN)
      • FIGURE 83     JAPAN DIGITAL DIABETES MARKET REVENUE, BY END-USER (2019 VS 2026) ($MN)
      • FIGURE 84     CHINA DIGITAL DIABETES MARKET REVENUE, BY PRODUCTS (2019 VS 2026) ($MN)
      • FIGURE 85     CHINA DIGITAL DIABETES DEVICES MARKET SHARE, BY PRODUCT TYPE (2019 VS 2026) ($MN)
      • FIGURE 86     CHINA DIGITAL DIABETES MARKET REVENUE, BY END-USER (2019 VS 2026) ($MN)
      • FIGURE 87     INDIA DIGITAL DIABETES MARKET REVENUE, BY PRODUCTS, (2019 VS 2026) ($MN)
      • FIGURE 88     INDIA DIGITAL DIABETES DEVICES MARKET REVENUE, BY PRODUCT TYPE (2019 VS 2026) ($MN)
      • FIGURE 89     INDIA DIGITAL DIABETES MARKET REVENUE, BY END-USER (2019 VS 2026) ($MN)
      • FIGURE 90     REST OF APAC DIGITAL DIABETES MARKET REVENUE, BY PRODUCTS, (2019 VS 2026) ($MN)
      • FIGURE 91     REST OF APAC DIGITAL DIABETES DEVICES MARKET REVENUE, BY PRODUCT TYPE (2019 VS 2026) ($MN)
      • FIGURE 92     REST OF APAC DIGITAL DIABETES MARKET REVENUE, BY END-USER (2019 VS 2026) ($MN)
      • FIGURE 93     ROW DIGITAL DIABETES MARKET SHARE, BY PRODUCTS (2019 VS 2026) (%)
      • FIGURE 94     ROW DIGITAL DIABETES DEVICES MARKET SHARE, BY PRODUCT TYPE (2019 VS 2026) (%)
      • FIGURE 95     ROW SBGM MARKET SHARE, BY PRODUCTS (2019 VS 2026) (%)
      • FIGURE 96     ROW CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019 VS 2026) ($MN)
      • FIGURE 97     ROW SMART INSULIN PUMP MARKET REVENUE, BY PRODUCT TYPE (2019 VS 2026) ($MN)
      • FIGURE 98     ROW DIGITAL DIABETES MARKET SHARE, BY END-USER (2019 VS 2026) (%)
      • FIGURE 99     ROW DIGITAL DIABETES MARKET SHARE, BY COUNTRY (2019 VS 2026) (%)
      • FIGURE 100     ROW SMART INSULIN PUMPS AND SMART INSULIN PENS MARKET PENETRATION, (2019)
      • FIGURE 101     BRAZIL DIGITAL DIABETES MARKET REVENUE, BY PRODUCTS, (2019 VS 2026) ($MN)
      • FIGURE 102     BRAZIL DIGITAL DIABETES DEVICES MARKET REVENUE, BY PRODUCT TYPE (2019 VS 2026) ($MN)
      • FIGURE 103     BRAZIL DIGITAL DIABETES MARKET REVENUE, BY END-USER (2019 VS 2026) ($MN)
      • FIGURE 104     REST OF LATIN AMERICA DIGITAL DIABETES MARKET REVENUE, BY PRODUCTS (2019 VS 2026) ($MN)
      • FIGURE 105     REST OF LATIN AMERICA DIGITAL DIABETES DEVICES MARKET REVENUE, BY PRODUCT TYPE (2019 VS 2026) ($MN)
      • FIGURE 106     REST OF LATIN AMERICA DIGITAL DIABETES MARKET REVENUE, BY END-USER (2019 VS 2026) ($MN)
      • FIGURE 107     MIDDLE EAST & OTHERS DIGITAL DIABETES MARKET REVENUE, BY PRODUCTS (2019 VS 2026) ($MN)
      • FIGURE 108     MIDDLE EAST & OTHERS DIGITAL DIABETES DEVICES MARKET REVENUE, BY PRODUCT TYPE (2019 VS 2026) ($MN)
      • FIGURE 109     MIDDLE EAST & OTHERS DIGITAL DIABETES MARKET REVENUE, BY END-USER (2019 VS 2026) ($MN)
      • FIGURE 110     KEY GROWTH STRATEGIES (2018-2019)
      • FIGURE 111     SWOT: ABBOTT LABORATORIES
      • FIGURE 112     SWOT: DEXCOM, INC.
      • FIGURE 113     SWOT: F.HOFFMAN-LA ROCHE AG
      • FIGURE 114     SWOT: INSULET CORPORATION
      • FIGURE 115     SWOT: I-SENS INC.
      • FIGURE 116     SWOT: LIVONGO HEALTH, INC.
      • FIGURE 117     SWOT: MEDTRONIC, PLC
      • FIGURE 118     SWOT: SENSEONICS HOLDINGS, INC.
      • FIGURE 119     SWOT: TANDEM DIABETES CARE
      • FIGURE 120     SWOT: YPSOMED HOLDING AG

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     ABBOTT LABORATORIES
      • 2     AGAMATRIX INC.
      • 3     AIRSTRIP TECHNOLOGIES
      • 4     A. MENARINI DIAGNOSTICS
      • 5     AMALGAM RX, INC.
      • 6     AMBROSIA SYSTEM INC
      • 7     APEX BIOTECHNOLOGY CORPORATION
      • 8     ARTELUS
      • 9     ARKRAY INC.
      • 10     ASCENSIA DIABETES CARE HOLDINGS AG
      • 11     AZUMIO
      • 12     B.BRAUN MELSUNGEN AG
      • 13     BEATO
      • 14     BECTON, DICKINSON & COMPANY
      • 15     BETACHEK
      • 16     BIOCHEMICAL SYSTEMS INTERNATIONAL
      • 17     BIOLAND TECHNOLOGY
      • 18     BIONIME CORPORATION
      • 19     BIOTELEMETRY INC
      • 20     BIOTEST MEDICAL CORPORATION
      • 21     BEURER GMBH
      • 22     BEIJING DNURSE TECHNOLOGIES CO.,LTD.
      • 23     BODYTEL GMBH
      • 24     BRIGHAM AND WOMEN'S HOSPITAL
      • 25     BRIGHTER AB
      • 26     CAREMATRIX, INC.
      • 27     CHIRONX
      • 28     COMPANION MEDICAL INC
      • 29     DARIOHEALTH CORPORATION
      • 30     DEBIOTECH S.A.
      • 31     DEXCOM, INC.
      • 32     DIABELOOP S.A.
      • 33     DIABNEXT
      • 34     DIAFYT MEDTECH
      • 35     DIAMESCO
      • 36     DIGITAL MEDICS PTY LTD
      • 37     DOTTLI
      • 38     DREAMED DIABETES LTD
      • 39     ELI LILLY AND CO.
      • 40     EMPERRA DIABETES CARE
      • 41     EMSIG GMBH CO.
      • 42     ENTRA HEALTH SYSTEMS
      • 43     EOFLOW
      • 44     F.HOFFMANN-LA ROCHE AG
      • 45     FIA BIOMED GMBH
      • 46     FITSCRIPT LLC
      • 47     FOODUCATE
      • 48     FORACARE, INC.
      • 49     GENDIUS
      • 50     GENESIS HEALTH TECHNOLOGY
      • 51     GLOOKO, INC.
      • 52     GLUCOME
      • 53     GLUCOSTRATUS LTD
      • 54     GLYSENS INCORPORATED
      • 55     GLYSURE LIMITED
      • 56     GLYTEC LLC
      • 57     GREINER BIO-ONE
      • 58     H2 INC(HEALTH2SYNC)
      • 59     HEALTHIFY ME
      • 60     HENIZ HERENZ MEDIZINALBEDARF GMBH
      • 61     IDEAL LIFE INC.
      • 62     I-HEALTH LAB INC.
      • 63     IME-DC GMBH
      • 64     INFORMED DATA SYSTEM INC (ONE DROP)
      • 65     INSULCLOCK
      • 66     INSULET CORPORATION
      • 67     INTUITY MEDICAL, INC
      • 68     I-SENS, INC.
      • 69     IXENSOR COMPANY LTD.
      • 70     JIANGSU DELFU MEDICAL DEVICE CO.,LTD
      • 71     JIANGSU HUIDA MEDICAL INSTRUMENTS CO., LTD
      • 72     KONINKLIJIKE PHILIPS B.V.
      • 73     L-TAC MEDICARE
      • 74     LIVONGO HEALTH, INC.
      • 75     LOBECK MEDICAL AG
      • 76     MEDISANA
      • 77     MEDTRONIC PLC
      • 78     MEDTRUM TECHNOLOGIES, INC.
      • 79     NOVONORDISK
      • 80     NU-BECA & MAXCELLENT CO.
      • 81     OK BIOTECH CO., LTD
      • 82     OSANG HEALTH CARE CO LTD
      • 83     OWEN MUMFORD
      • 84     PEPEX BIOMEDICAL, INC.
      • 85     PHARMA TECH SOLUTIONS, INC.
      • 86     PHILOSYS INC
      • 87     PLATINUM EQUITY (LIFE SCAN INC)
      • 88     POPS DIABETES CARE INC
      • 89     PRODIGY DIABETES CARE, LLC
      • 90     SAIFY TRADERS
      • 91     SANOFI S.A.
      • 92     SARSTEDT
      • 93     SD BIOSENSOR
      • 94     SENSEONICS HOLDINGS, INC.
      • 95     SENSYNE HEALTH
      • 96     SIRMA MEDICAL SYSTEMS
      • 97     SMART METER LLC
      • 98     SOCIAL DIABETES, S.L.
      • 99     SOOIL DEVELOPMENT CO., LTD
      • 100     SPIKE
      • 101     SWEETCH
      • 102     TAIDOC TECHNOLOGY CORPORATION
      • 103     TANDEM DIABETES CARE
      • 104     TIANJIN EMPECS MEDICAL DEVICE CO.,LTD.
      • 105     TIDEPOOL
      • 106     TERUMO CORPORATION
      • 107     TRIVIDEA HEALTH, INC
      • 108     TYSON BIORESEARCH INC
      • 109     UT SOUTHWESTERN MEDICAL CENTER
      • 110     VALERITAS INC.
      • 111     VICENTRA B.V.
      • 112     VIRTAHEALTH CORP
      • 113     VIVACHEK LABORATORIES, INC.
      • 114     VOLUNTIS
      • 115     WELLDOC, INC.
      • 116     WELLSPAN HEALTH
      • 117     YPSOMED HOLDING AG
      • 118     ZHEJIANG POCTECH CO.,LTD